BWAY vs. BLUA, SRTS, ALUR, KRMD, STIM, PDEX, NVNO, MGRM, SEPA, and HSAQ
Should you be buying BrainsWay stock or one of its competitors? The main competitors of BrainsWay include BlueRiver Acquisition (BLUA), Sensus Healthcare (SRTS), Allurion Technologies (ALUR), KORU Medical Systems (KRMD), Neuronetics (STIM), Pro-Dex (PDEX), enVVeno Medical (NVNO), Monogram Orthopaedics (MGRM), SEP Acquisition (SEPA), and Health Sciences Acquisitions Co. 2 (HSAQ). These companies are all part of the "surgical & medical instruments" industry.
BlueRiver Acquisition (NYSE:BLUA) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.
BrainsWay has higher revenue and earnings than BlueRiver Acquisition.
In the previous week, BrainsWay had 7 more articles in the media than BlueRiver Acquisition. MarketBeat recorded 8 mentions for BrainsWay and 1 mentions for BlueRiver Acquisition. BlueRiver Acquisition's average media sentiment score of 0.67 beat BrainsWay's score of 0.00 indicating that BrainsWay is being referred to more favorably in the news media.
BrainsWay has a consensus price target of $13.00, suggesting a potential upside of 141.64%. Given BlueRiver Acquisition's higher probable upside, analysts plainly believe BrainsWay is more favorable than BlueRiver Acquisition.
BrainsWay received 62 more outperform votes than BlueRiver Acquisition when rated by MarketBeat users.
BlueRiver Acquisition has a net margin of 0.00% compared to BlueRiver Acquisition's net margin of -4.83%. BrainsWay's return on equity of 0.00% beat BlueRiver Acquisition's return on equity.
22.3% of BlueRiver Acquisition shares are held by institutional investors. Comparatively, 30.1% of BrainsWay shares are held by institutional investors. 79.0% of BlueRiver Acquisition shares are held by insiders. Comparatively, 19.0% of BrainsWay shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
BrainsWay beats BlueRiver Acquisition on 9 of the 12 factors compared between the two stocks.
Get BrainsWay News Delivered to You Automatically
Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BrainsWay Competitors List
Related Companies and Tools
